Compare SoFi Technologies Inc (SOFI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs Twist Bioscience Corp — how do they compare? SoFi Technologies Inc trades at $17.35 (market cap $23.26B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: SoFi Technologies Inc is far larger — about 2.8× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| SOFI | TWST | |
|---|---|---|
Market Cap | $23.26B | $8.42B |
Sector | Financials | Health |
52-Week High | $32.21 | $153.10 |
52-Week Low | $15.15 | $24.16 |
Enterprise Value | — | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoFi Technologies trades at $18.01, down 1.15% amid mixed signals. The stock shows strong fundamental progress with 40% revenue growth and three consecutive earnings beats, though Q3 2026 expectations of $0.17 EPS present a high bar. Technical indicators are neutral with support at $18 and resistance at $19. Recent partnership with Payward expands banking infrastructure capabilities while rising Treasury yields pressure fintech lenders.
SoFi presents a growth story with expanding profitability and strategic partnerships, though negative operating cash flow and high valuation multiples warrant caution. Analyst consensus targets $20.78 with 37% buy ratings, suggesting moderate upside potential balanced against macroeconomic sensitivity and competitive pressures in the digital banking space.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
